000123847 001__ 123847
000123847 005__ 20240731103312.0
000123847 0247_ $$2doi$$a10.1016/j.jdin.2022.11.009
000123847 0248_ $$2sideral$$a132418
000123847 037__ $$aART-2023-132418
000123847 041__ $$aeng
000123847 100__ $$aChernyshov, P. V.
000123847 245__ $$aSensitivity to treatment and score bands of the infants and toddlers dermatology quality of life questionnaire
000123847 260__ $$c2023
000123847 5060_ $$aAccess copy available to the general public$$fUnrestricted
000123847 5203_ $$aBackground: The Infants and Toddlers Dermatology Quality of Life (InToDermQoL) questionnaire is the first dermatology-specific proxy health related QoL instrument for children from birth to 4 years. Score meaning bands and the sensitivity to successful therapeutic intervention are important to interpret the clinical meaning of an instrument. Objective: The aim of the present study was to check the sensitivity to successful therapeutic intervention and establish score bands of the InToDermQoL questionnaire. Methods: Parents or grandparents of 424 children with skin diseases from Spain, Malta, Croatia, Romania, Greece, and Ukraine filled in national language versions of the InToDermQoL questionnaire. Disease severity of children with atopic dermatitis was assessed by SCORAD (Scoring atopic dermatitis). Cohen’s d was used to assess the responsiveness of the instrument. Results: The mean total InToDermQoL scores significantly decreased after treatment. Severity grading of the SCORAD scores gave stratification of the InToDermQoL severity grades based on 95% confidence intervals. Scores below a calculated minimal important difference of 2 corresponded to no effect on patient’s health related QoL. Limitations: Score banding may be slightly different across patient population and study context. Conclusion: All 3 age-specific versions of the InToDermQoL questionnaire showed sensitivity to treatment. Score bands for the InToDermQoL questionnaire have been established.
000123847 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000123847 592__ $$a1.162$$b2023
000123847 593__ $$aDermatology$$c2023$$dQ1
000123847 594__ $$a3.6$$b2023
000123847 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000123847 700__ $$0(orcid)0000-0001-5632-0351$$aMarrón, S. E.$$uUniversidad de Zaragoza
000123847 700__ $$aBoffa, M. J.
000123847 700__ $$aPustišek, N.
000123847 700__ $$aManolache, L.
000123847 700__ $$aKakourou, T.
000123847 700__ $$aCachia, M.
000123847 700__ $$aSvyatenko, T.
000123847 700__ $$aKoumaki, D.
000123847 700__ $$aChernyshov, A. V.
000123847 700__ $$0(orcid)0000-0003-1917-6906$$aTomas-Aragonés, L.
000123847 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología
000123847 773__ $$g10 (2023), 61-67$$tJAAD International$$x2666-3287
000123847 8564_ $$s220509$$uhttps://zaguan.unizar.es/record/123847/files/texto_completo.pdf$$yVersión publicada
000123847 8564_ $$s2137135$$uhttps://zaguan.unizar.es/record/123847/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000123847 909CO $$ooai:zaguan.unizar.es:123847$$particulos$$pdriver
000123847 951__ $$a2024-07-31-09:39:50
000123847 980__ $$aARTICLE